Calidi Biotherapeutics Inc (CLDI) saw an uptrend of 20.18% in the recent trading with $0.71 being its most recent. The current price level -81.66% lower than the highest price of $3.89 marked by the stock while trading over the past 52-weeks, whereas it is 251.95% higher than the lowest price of $0.20 the company dropped to over past 52-weeks. The latest news story on CLDI appeared in (PR Newswire) under the title “Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up” on Jul-10-25.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Calidi Biotherapeutics Inc Earnings – What Happened With CLDI
Coming around sales and income figures on CLDI Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Calidi Biotherapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 34.52 million. CLDI does have institutional investors; and they hold 15.78% of the stock.
As on 2024-06-30, RED WAVE INVESTMENTS LLC was the top most holder in Calidi Biotherapeutics Inc (AMEX:CLDI) with an ownership of 0.62 million shares of the company or 1.1723 of the stake worth $0.12 million. The filing also reveals CPR INVESTMENTS INC. as the second largest holder in the company with a control over 1.0511 of the outstanding shares. Its stake is worth $0.11 million for having 0.56 million shares in hand.
RS CRUM INC. also came holding a key position in the company during the recent quarter and it now holds 0.4945 of the outstanding shares. With this there are now 39.0 institutions which have possession in CLDI’s shares.
Key Metrics forCLDI
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Calidi Biotherapeutics Inc has a debt to equity ratio of 0.68.
